Corvus Pharmaceuticals CRVS
NASDAQ CRVS
$14.39 -0.26 (-1.77%)
As of: Sep 4, 2026 · 3:59 PM EDT

Corvus Pharmaceuticals (CRVS) Cash from Operations Growth (5y) (2020 - 2026)

Analysis

Corvus Pharmaceuticals (CRVS) Cash from Operations Growth (5y) (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Corvus Pharmaceuticals 1.33 Bn 1.12 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -4.01%
Mar 31, 2026 -3.38%
Dec 31, 2025 -2.29%
Sep 30, 2025 -4.35%
Jun 30, 2025 9.44%
Mar 31, 2025 2.45%
Dec 31, 2024 0.11%
Sep 30, 2024 9.83%
Jun 30, 2024 9.87%
Mar 31, 2024 10.52%
Dec 31, 2023 8.95%
Sep 30, 2023 12.83%
Jun 30, 2023 13.67%
Mar 31, 2023 5.99%
Dec 31, 2022 7.22%
Sep 30, 2022 8.45%
Jun 30, 2022 12.16%
Mar 31, 2022 12.81%
Dec 31, 2021 6.13%
Sep 30, 2021 -4.74%